Answers are grounded in this paper and cite their sources.
The hypoxia-inducible factor (HIF) coordinates the response of tumors to low oxygen by stimulating genes involved in metabolism and angiogenesis. HIF pathway activation is highly associated with tumor progression and radiotherapy resistance. Ligands that target this pathway are potential agents for the treatment of solid tumor malignancies. We developed an L-RNA aptamer, L-Apt5–4, targeting the HIF-1α promoter DNA G-quadruplex (dG4) via mirror-image SELEX. This L-RNA aptamer adopts a stem-loop secondary structure, binds HIF-1α dG4 with high affinity and specificity, and enters the nucleus to effectively downregulate HIF-1α and its downstream targets in cancer cells. By suppressing HIF-1α, L-Apt5–4 not only inhibits tumor cell proliferation, migration, and invasion, but also acts as a potent radiosensitizer, synergizing with radiotherapy to enhance cancer cell death. The combination therapy significantly suppresses tumor growth and metastasis while exhibiting excellent biosafety in vivo. Thus, L-Apt5–4 represents a novel HIF-1α-targeted therapeutic and radiosensitizer for combined cancer treatment.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: